Guidelines for Trigger Timing and Cycle Cancellation in IUI with Ovarian Stimulation

Primary Follicular Cancellation Criteria

Cancel the IUI cycle when more than 2 follicles are ≥ 15 mm at the time of planned hCG or LH surge, to avoid life‑threatening multiple pregnancy and ovarian hyperstimulation syndrome (moderate‑quality evidence) 1.
Cancel the IUI cycle when more than 5 follicles are ≥ 10 mm at the time of planned hCG or LH surge, for the same safety reasons (moderate‑quality evidence) 1.
The risk of multiple pregnancy rises sharply with increasing dominant follicle count: approximately 6 % with 2 follicles, 14 % with 3 follicles, and 10 % with 4 follicles (moderate‑quality evidence) 3.

Positive pregnancy test (endogenous hCG present) – trigger must be withheld. 4
Uncontrolled thyroid disease – patient must be euthyroid before proceeding. 4
Severe hypertension – pregnancy is contraindicated. 4
Active pelvic infection – risk of ascending infection with instrumentation. 4
Documented hypersensitivity to hCG or GnRH‑agonist – trigger must be avoided. 4
Significant cardiac disease where pregnancy poses unacceptable risk. 4
Therapeutic anticoagulation – increased bleeding risk with IUI procedure. 4
Recent ovarian surgery – concerns about structural integrity of the ovary. 4
Severe endometriosis with marked anatomical distortion. 4

GnRH‑agonist triggers should not be used in IUI cycles as an alternative to cycle cancellation; they do not improve pregnancy rates and increase multiple‑pregnancy risk and cost (high‑quality evidence) 1.
International fertility guidelines explicitly recommend against GnRH‑agonist use in stimulated IUI for the reasons above (high‑quality evidence) 1.
GnRH‑agonist triggers are reserved for IVF cycles employing GnRH‑antagonist protocols and are not appropriate for IUI (moderate‑quality evidence) 4.

Aspiration of excess follicles at the time of planned trigger may reduce the risk of multiple pregnancy; supported by low‑quality evidence. 1

Use low‑dose gonadotropins (≤ 75 IU/day) instead of higher doses; yields comparable pregnancy rates with lower multiple‑pregnancy rates (moderate‑quality evidence) 1.
Consider clomiphene citrate or tamoxifen as first‑line agents; they produce lower multiple‑pregnancy rates, though live‑birth rates are slightly reduced compared with gonadotropins (moderate‑quality evidence) 1.
Avoid adding GnRH‑agonist to gonadotropins in IUI protocols, as this increases multiple‑pregnancy rates without improving outcomes (high‑quality evidence) 1.

Do not substitute a GnRH‑agonist trigger for hCG in IUI cycles; this approach is only appropriate in IVF protocols (moderate‑quality evidence) 3.
Do not proceed with trigger hoping for later selective reduction; primary prevention via appropriate cancellation is the evidence‑based strategy (moderate‑quality evidence) 3.
Do not use higher gonadotropin doses (> 75 IU/day) under the assumption that more stimulation improves outcomes; higher doses increase complications without benefit (high‑quality evidence) 1.
Do not rely solely on estradiol levels to decide on cancellation; follicle count remains the primary determinant (high‑quality evidence) 1.